[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse SLC2A3

Summary
SymbolSLC2A3
Namesolute carrier family 2 (facilitated glucose transporter), member 3
Aliases GLUT3; GLUT-3; glucose transporter type 3, brain; Solute carrier family 2, facilitated glucose transporter m ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF00083 Sugar (and other) transporter
Function

Facilitative glucose transporter that can also mediate the uptake of various other monosaccharides across the cell membrane (PubMed:9477959, PubMed:26176916). Mediates the uptake of glucose, 2-deoxyglucose, galactose, mannose, xylose and fucose, and probably also dehydroascorbate (PubMed:9477959, PubMed:26176916). Does not mediate fructose transport (PubMed:9477959, PubMed:26176916).

> Gene Ontology
 
Biological Process GO:0006766 vitamin metabolic process
GO:0006767 water-soluble vitamin metabolic process
GO:0006820 anion transport
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0015711 organic anion transport
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0019852 L-ascorbic acid metabolic process
GO:0034219 carbohydrate transmembrane transport
GO:0035428 hexose transmembrane transport
GO:0051180 vitamin transport
GO:0070837 dehydroascorbic acid transport
GO:1904659 glucose transmembrane transport
Molecular Function GO:0005355 glucose transmembrane transporter activity
GO:0005536 glucose binding
GO:0015144 carbohydrate transmembrane transporter activity
GO:0015145 monosaccharide transmembrane transporter activity
GO:0015149 hexose transmembrane transporter activity
GO:0030246 carbohydrate binding
GO:0033300 dehydroascorbic acid transporter activity
GO:0048029 monosaccharide binding
GO:0051119 sugar transmembrane transporter activity
GO:0051183 vitamin transporter activity
GO:0055056 D-glucose transmembrane transporter activity
GO:1901476 carbohydrate transporter activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-428790: Facilitative Na+-independent glucose transporters
R-HSA-70153: Glucose transport
R-HSA-189200: Hexose transport
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-6798695: Neutrophil degranulation
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425366: Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
R-HSA-196836: Vitamin C (ascorbate) metabolism
Summary
SymbolSLC2A3
Namesolute carrier family 2 (facilitated glucose transporter), member 3
Aliases GLUT3; GLUT-3; glucose transporter type 3, brain; Solute carrier family 2, facilitated glucose transporter m ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC2A3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSLC2A3
Namesolute carrier family 2 (facilitated glucose transporter), member 3
Aliases GLUT3; GLUT-3; glucose transporter type 3, brain; Solute carrier family 2, facilitated glucose transporter m ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC2A3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.51 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSLC2A3
Namesolute carrier family 2 (facilitated glucose transporter), member 3
Aliases GLUT3; GLUT-3; glucose transporter type 3, brain; Solute carrier family 2, facilitated glucose transporter m ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC2A3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4720.309
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1440.952
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6970.651
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6230.306
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5750.8
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6680.838
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0480.941
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4210.833
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5630.775
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.410.81
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8540.736
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0230.915
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC2A3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC2A3
Namesolute carrier family 2 (facilitated glucose transporter), member 3
Aliases GLUT3; GLUT-3; glucose transporter type 3, brain; Solute carrier family 2, facilitated glucose transporter m ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC2A3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC2A3
Namesolute carrier family 2 (facilitated glucose transporter), member 3
Aliases GLUT3; GLUT-3; glucose transporter type 3, brain; Solute carrier family 2, facilitated glucose transporter m ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC2A3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC2A3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC2A3
Namesolute carrier family 2 (facilitated glucose transporter), member 3
Aliases GLUT3; GLUT-3; glucose transporter type 3, brain; Solute carrier family 2, facilitated glucose transporter m ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC2A3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC2A3
Namesolute carrier family 2 (facilitated glucose transporter), member 3
Aliases GLUT3; GLUT-3; glucose transporter type 3, brain; Solute carrier family 2, facilitated glucose transporter m ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC2A3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC2A3
Namesolute carrier family 2 (facilitated glucose transporter), member 3
Aliases GLUT3; GLUT-3; glucose transporter type 3, brain; Solute carrier family 2, facilitated glucose transporter m ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC2A3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC2A3
Namesolute carrier family 2 (facilitated glucose transporter), member 3
Aliases GLUT3; GLUT-3; glucose transporter type 3, brain; Solute carrier family 2, facilitated glucose transporter m ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC2A3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.